Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.95
PXSLY's Cash to Debt is ranked higher than
72% of the 1158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. PXSLY: 2.95 )
PXSLY' s 10-Year Cash to Debt Range
Min: 2.95   Max: No Debt
Current: 2.95

Equity to Asset 0.27
PXSLY's Equity to Asset is ranked lower than
51% of the 965 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. PXSLY: 0.27 )
PXSLY' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.98
Current: 0.27

0.27
0.98
F-Score: 2
Z-Score: -8.18
M-Score: -4.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -878.64
PXSLY's Operating margin (%) is ranked lower than
55% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. PXSLY: -878.64 )
PXSLY' s 10-Year Operating margin (%) Range
Min: -1310600   Max: -990.13
Current: -878.64

-1310600
-990.13
Net-margin (%) -661.96
PXSLY's Net-margin (%) is ranked lower than
55% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.46 vs. PXSLY: -661.96 )
PXSLY' s 10-Year Net-margin (%) Range
Min: -1023200   Max: -1028.95
Current: -661.96

-1023200
-1028.95
ROE (%) -144.97
PXSLY's ROE (%) is ranked lower than
56% of the 1135 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.08 vs. PXSLY: -144.97 )
PXSLY' s 10-Year ROE (%) Range
Min: -120.56   Max: -20.89
Current: -144.97

-120.56
-20.89
ROA (%) -52.29
PXSLY's ROA (%) is ranked lower than
54% of the 1169 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. PXSLY: -52.29 )
PXSLY' s 10-Year ROA (%) Range
Min: -57.89   Max: -19.68
Current: -52.29

-57.89
-19.68
ROC (Joel Greenblatt) (%) -206.29
PXSLY's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.30 vs. PXSLY: -206.29 )
PXSLY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1116.55   Max: -152.22
Current: -206.29

-1116.55
-152.22
Revenue Growth (3Y)(%) 26.00
PXSLY's Revenue Growth (3Y)(%) is ranked higher than
93% of the 948 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. PXSLY: 26.00 )
PXSLY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 26
Current: 26

0
26
EBITDA Growth (3Y)(%) -17.80
PXSLY's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. PXSLY: -17.80 )
PXSLY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.8   Max: 91.3
Current: -17.8

-17.8
91.3
EPS Growth (3Y)(%) -5.30
PXSLY's EPS Growth (3Y)(%) is ranked higher than
68% of the 822 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. PXSLY: -5.30 )
PXSLY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.6   Max: 122.4
Current: -5.3

-12.6
122.4
» PXSLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with PXSLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.00
PXSLY's P/B is ranked higher than
61% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. PXSLY: 5.00 )
PXSLY' s 10-Year P/B Range
Min: 0.3   Max: 5.82
Current: 5

0.3
5.82
P/S 7.41
PXSLY's P/S is ranked lower than
54% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.25 vs. PXSLY: 7.41 )
PXSLY' s 10-Year P/S Range
Min: 2.3   Max: 297
Current: 7.41

2.3
297
Current Ratio 4.94
PXSLY's Current Ratio is ranked higher than
87% of the 1028 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. PXSLY: 4.94 )
PXSLY' s 10-Year Current Ratio Range
Min: 4.94   Max: 44.5
Current: 4.94

4.94
44.5
Quick Ratio 4.68
PXSLY's Quick Ratio is ranked higher than
88% of the 1028 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. PXSLY: 4.68 )
PXSLY' s 10-Year Quick Ratio Range
Min: 4.68   Max: 44.5
Current: 4.68

4.68
44.5
Days Inventory 368.26
PXSLY's Days Inventory is ranked higher than
55% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 141.66 vs. PXSLY: 368.26 )
PXSLY' s 10-Year Days Inventory Range
Min: 247.58   Max: 9125
Current: 368.26

247.58
9125
Days Sales Outstanding 634.81
PXSLY's Days Sales Outstanding is ranked higher than
55% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. PXSLY: 634.81 )
PXSLY' s 10-Year Days Sales Outstanding Range
Min: 207.4   Max: 26918.75
Current: 634.81

207.4
26918.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.00
PXSLY's Price/Tangible Book is ranked higher than
72% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. PXSLY: 5.00 )
PXSLY' s 10-Year Price/Tangible Book Range
Min: 0.78   Max: 7.48
Current: 5

0.78
7.48
Price/Median PS Value 0.10
PXSLY's Price/Median PS Value is ranked higher than
100% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. PXSLY: 0.10 )
PXSLY' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 2.18
Current: 0.1

0.04
2.18
Earnings Yield (Greenblatt) -212.80
PXSLY's Earnings Yield (Greenblatt) is ranked lower than
65% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. PXSLY: -212.80 )
PXSLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -212.8   Max: 3231.7
Current: -212.8

-212.8
3231.7

Analyst Estimate

Jun15
EPS($) -0.79
EPS without NRI($) -0.79

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:PXS.Australia, UUD.Germany,
Pharmaxis Limited is an Australian specialty pharmaceutical company involved in the research, development and commercialization of healthcare products for chronic respiratory and immune diseases. The company produces Aridol, a powder which is used for the diagnosis and management of asthma and chronic obstructive pulmonary diseases. The company has sales and marketing group in Australia and has appointed marketing and distribution partners for certain European and Asian territories with respect to the marketing and sale of Aridol. They also manufacture Bronchitol, a drug used for chronic obstructive lung diseases like cystic fibrosis, bronchiectasis, and chronic bronchitis. The company has established offices In order to commercialize this product.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK